Download
Download by
Scanning QR Code
Download app
Download app

港股异动 | 四环医药(0460.HK)涨超5% 轩竹生物吡罗西尼获批开展三期临床试验

格隆汇 ·  {{timeTz}}
格隆汇11月25日丨四环医药(0460.HK)午后扩大涨幅,现报1.61港元,涨幅5.23%,总市值152.2亿港元。公司公告称,集团旗下轩竹生物已收到中国国家药品监督管理局药品审评中心同意在研1类创新药吡罗西尼开展三期临床试验的申请。临床前研究结果表明,吡罗西尼具有独特的药代动力学特征,能够有效通过血脑屏障,对乳腺癌脑转移的患者和脑癌患者预期会产生良好疗效。

This page is machine-translated. Futubull tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

Back to the Top